Tissue Therapies patent accepted in Australia
Tuesday, 31 May, 2005
The core patent for Tissue Therapies' (ASX:TIS) VitroGro growth factor complex, used to accelerate wound healing, has been accepted in Australia.
The acceptance follows the granting of the core VitroGro patent in New Zealand in March, the first jurisdiction to do so.
Tissue Therapies has worldwide exclusive rights to commercialise VitroGro under an IP Agreement with the Queensland University of Technology, and will also seek core patents for VitroGro in other jurisdictions such as the USA, Canada, Europe, South Korea, China and Japan.
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
